Romidepsin Treatment in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review and Meta-Analysis

Am J Ther. 2022 Sep-Oct;29(5):e589-e592. doi: 10.1097/MJT.0000000000001419. Epub 2021 Jul 9.

Authors

Waleed Abdulsattar¹, Azizullah Beran¹, Ali Alqahtani², Ziad Abuhelwa¹, Mohammed Mhanna¹, Abdurahman Alloghbi³, Omar Srour¹, Hazem Ayesh¹, Danae Hamouda⁴

Affiliations

¹ Department of Internal Medicine, University of Toledo, Toledo, OH.
² Department of Hematology and Oncology, Georgetown University, Washington, DC.
³ Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
⁴ Department of Hematology and Oncology, University of Toledo, Toledo, OH.

PMID: 34264886
DOI: 10.1097/MJT.0000000000001419

No abstract available

Publication types

Meta-Analysis
Systematic Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Depsipeptides* / therapeutic use
Disease-Free Survival
Humans
Lymphoma, T-Cell, Peripheral* / chemically induced
Lymphoma, T-Cell, Peripheral* / drug therapy

Substances

Depsipeptides
romidepsin